🟢 Eupraxia Pharmaceuticals is trading 6% up today after Q2 earnings beat

Eupraxia Pharmaceuticals is trading 5.71% up now at $6.85 after its August 11, 2026 second-quarter earnings beat.

• The results were supported by a $133.6 million liquidity position and cash runway into the second half of 2028.
• Management highlighted improving fibrosis and inflammation data for EP-104GI and expects interim Phase 2b RESOLVE results in Q4 2026.
• Broader risk-on sentiment following cooler U.S. inflation is providing additional support.